Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DPR000079

Drug Information
SynonymsHMS502C15; EINECS 257-431-4; N-[4-Nitro-2-phenoxyphenyl]-methanesulfonamide; MLS001148268; Guaxan; Nimesulidum [INN-Latin]; SMR000058484; SBB066407; NCGC00015725-01; EU-0100855; C012655; HMS1922K17; CHEMBL56367; Therabel Brand of Nimesulide; Aldoron; HMS1792G05; Flogovital; Nimedex; NCGC00021842-03; Lopac0_000855; Nimesulide [BAN:INN]; SPBio_001382; BSPBio_003112; KBio3_000826; Alcala Brand of Nimesulide; KBio2_000443; MLS000069680; Sulidene; R-805; Nexen; AC-4524; BCBcMAP01_000034; KBio2_007193; KBio3_000825; D01049; NCGC00015725-12; Prestwick2_000194; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CID4495; N1016_SIGMA; Nisulid; Helsinn Brand of Nimesulide; Mesulid; NCGC00021842-07; BPBio1_000163; Ergha Brand of Nimesulide; NCGC00021842-05; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Bio2_000382; Prestwick3_000194; NCGC00021842-04; Aulin; 4'-Nitro-2'-phenoxymethanesulfonanilide; Bio2_000862; BSPBio_001103; BRD-K76775527-001-06-2; BRN 2421175; Eskaflam; Nimesulide (JAN/INN); SmithKline Beecham Brand of Nimesulide; N 1016; Nise Gel; 4'-Nitro-2'-phenoxymethansulfonanilid; Maver Brand of Nimesulide; KBioSS_002057; AB00052332; Spectrum2_001541; Orthobid; HMS1990G05; CCRIS 8225; LS-90290; MolPort-003-849-391; Spectrum_001577; Prestwick_618; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI); Nimed; NCGC00015725-02; NIM-03; KBio1_000693; Nimesulidum; Nimesulida [INN-Spanish]; KBio2_005579; Alter Brand of Nimesulide; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; C13H12N2O5S; Redaflam; Prestwick0_000194; IDI1_002137; Nimesil; NCGC00015725-03; HMS1568H09; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; NCGC00021842-06; NCGC00015725-06; KBioGR_000443; lizepat; Lopac-N-1016; IDI1_000693; R 805; CHEBI:44445; HMS2089B14; NIM; STL018679; DivK1c_000693; 4-Nitro-2-phenoxy-methanesulfonanilide; Nimesulida; SPBio_002068; KBioSS_000443; NINDS_000693; Prestwick1_000194; Spectrum3_001576; Spectrum5_000964; KBio2_003011; NCGC00021842-08; SPECTRUM1503231; 51803-78-2; Lakeside Brand of Nimesulide; KBio2_002057; Antifloxil; DB04743; BSPBio_000147; nchembio.147-comp1; nimesulide; KBioGR_000695; HMS1362G05; AC1L1IAM; Spectrum4_000178; KBio2_004625; KBio3_002612; CAS-51803-78-2    
IndicationAcute pain; fever; osteoarthritis; dysmenorrheaPreclinical    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnalgesics    
CAS NumberCAS 51803-78-2
PubChem Compound IDCID 4495.    
PubChem Substance IDSID 181050.    
SuperDrug ATC IDM01AX17;    
SuperDrug CAS ID051803782;    
TargetProstaglandin G/H synthase 2 Inhibitor[1]
Ref 1Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543